The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea.
Dallas, TX (PRWEB) September 15, 2014
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc.
Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.
Order a copy of this report at http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114908 .
The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.
Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST’s adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).
Complete report is available at http://www.chinamarketresearchreports.com/114908.html .
In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.
Global and China Stem Cell Industry Report, 2014-2017 highlights the followings:
Classification, application, industry chain definition, etc. of stem cells;
Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;
Policies, upstream/midstream/downstream development, etc. of China stem cell industry;
Operation, stem cell business, etc. of 6 upstream companies and 18 midstream/downstream companies worldwide.
Few Points from Table of Contents
List of Charts
Classification of Stem Cell
Overview of Stem Cell Therapy Area (by Disease Type)
Advantages and Disadvantages of Stem Cell Therapy
Source and Application of Adult Stem Cells (by Type)
Stem Cell Industry Chain
Industry Chain Distribution of Major Global Stem Cell Enterprises
Global Authorized Stem Cell Products and Their Clinical Application
Major Products under Development, Therapeutic Area and Clinical Trial Stage of Global Stem Cell Therapy as of 2014H1
Global Stem Cell Market Size and YoY Growth, 2007-2013
Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2013
Clinical Application of Global Stem Cell Technology (by Disease Type), 2013
Cord Blood Bank Distribution in Major Countries as of 2014H1
Cord Blood Application in Major Countries
Global Top 10 Death Causes (by Death Toll), 2012
Global Top 10 Death Causes (by Income Group), 2012
Global Top 10 Death Causes in Low-income Countries, 2012
Global Top 10 Death Causes in Low- and Middle-income Countries, 2012
Global Top 10 Death Causes in Middle- and High-income Countries, 2012
Global Top 10 Death Causes in High-income Countries, 2012
ChinaMarketResearchReports.com (http://www.chinamarketresearchreports.com/ .) is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.